Monitor for further insider selling filings and any material news that could explain the accelerated selling. The pattern suggests potential lack of confidence from a former officer; traders may consider reducing exposure or hedging ahead of any upcoming catalysts.
TARS drugs
TARS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $82.76entry
- T+1 · 3mo ago +0.54%α −0.51% · $83.21
- T+5 · 2mo ago −1.98%α −1.02% · $81.12
- T+20 · 7w ago −5.01%α −4.68% · $78.61
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Former officer Aziz Mottiwala filed a Form 144 notice to sell 77,698 shares (~$5.75M) of Tarsus Pharmaceuticals on September 1, 2026, following two recent large sales totaling ~$9.68M on August 19 and August 25. This pattern of accelerated insider selling by a former officer raises concern about insider sentiment despite strong analyst consensus.
Key Facts
- Aziz Mottiwala, a former officer, filed Form 144 to sell 77,698 shares of common stock.
- Estimated aggregate market value of proposed sale: $5,746,846.04.
- Shares acquired via stock option exercise on the same date (September 1, 2026).
- Mottiwala previously sold 53,043 shares on August 19, 2026, and 81,332 shares on August 25, 2026.
- Total insider sales by Mottiwala in the past two weeks exceed $15 million.
- Market cap of TARS is ~$3.3B; proposed sale represents ~0.17% of market cap.
Financial Impact
Proposed sale of 77,698 shares valued at ~$5.75M; combined with recent sales totals ~$15.4M in two weeks.
Risk Factors
- Continued insider selling could signal deteriorating confidence in the company's near-term prospects.
- Large option-exercise sales may indicate the insider is monetizing equity ahead of a potential downturn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-006607 |
| Document: 0001959173-26-006607-index.html | 0001959173-26-006607 |
| Document: 0001959173-26-006607.txt | 0001959173-26-006607 |
Track record
21 reports on TARS
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers